Search Results

You are looking at 51 - 59 of 59 items for :

  • "heart transplantation" x
  • Medical and Health Sciences x
  • Refine by Access: All Content x
Clear All
Orvosi Hetilap
Authors: Krisztina Czebe, Balázs Antus, Marina Varga, and Eszter Csiszér

Mattner, F., Fischer, S., Weissbrodt, H. és mtsai: Post-operative nosocomial infections after lung and heart transplantation. J. Heart Lung Transplant., 2007, 26 , 241–249. Weissbrodt H

Restricted access

.: Fatal nosocomial Legionnaires’ disease after heart transplantation: Clinical course, epidemiology and prevention strategies for the highly immunocompromised host. J. Hosp. Infect. 43 , 242–246 (1999). Junge

Restricted access

interaction between erlotinib and simvastatin Clin. Lung Cancer 9 232 – 234 . [22]. D. V. Vlahakos A. Manginas D. Chilidou 2002 Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with

Restricted access
Orvosi Hetilap
Authors: Árpád Czifra, Alida Páll, Veronika Sebestyén, Kitti Barta, István Lőrincz, József Balla, György Paragh, and Zoltán Szabó

–405. Zabel, M., Franz, M. R., Siedow, A., et al.: QT dispersion as a marker of risk in patients awaiting heart transplantation? J. Am. Coll. Cardiol., 1998, 31 (6), 1442–1443. Baczkó, I.: Pharmacologically impaired

Restricted access

–415. Chin, C., Chen, G., Sequeria, F., et al.: Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant., 2011, 30 (2), 158

Open access

Przybylowski, P., Malyszko, J., Malyszko, J. S.: Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant. Proc., 2010, 42 , 1808–1811. Malyszko J. S

Open access
Orvosi Hetilap
Authors: Péter Apor, Máté Petrekanich, and Júlianna Számadó

variability after heart transplantation: 10-year follow-up. Transplantation, 2004, 78 , 1523–1531. Speijer G. Different evolutions in heart rate variability after heart transplantation

Open access

Szabó G, Bahrle S, Stumpf N, Sonnenberg K, Szabó E, Pacher P, Csont T, Schulz R, Dengler TJ, Liaudet L, Jagtap PG, Southan GJ, Vahl CF, Hagl S, Szabó C: Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ

Restricted access

CDI, but more accurate studies of this phenomenon are necessary [ 12 ]. Other significant risk factors for CDI are immunosuppression, e.g., in transplant patients, especially heart transplants, as well as cystic fibrosis, vitamin D deficiency

Restricted access